@paucapetillog's GLP-1 response video, fact-checked
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications that activate incretin pathways to reduce appetite and slow gastric emptying. Clinical trials show 15-21% average weight loss with continued use, but effects diminish when treatment stops.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
Pau Capetillo (@paucapetillog) posted a response video on TikTok addressing accusations about GLP-1 medications, racking up 2.2 million views. Without being able to see the specific claims made in this response video, we can't evaluate the accuracy of their statements about semaglutide, tirzepatide, or related medications.
What does this video actually claim?
The video appears to be Capetillo's response to user @Kika25, calling it their "favorite accusation." However, without access to the actual video content, we can't identify the specific claims being made about GLP-1 receptor agonists like Ozempic, Wegovy, or Mounjaro.
This is problematic because GLP-1 content on social media often contains misinformation. The STEP trials for semaglutide and SURMOUNT trials for tirzepatide provide clear data on these medications' efficacy and side effects. Any discussion of these drugs should reference actual clinical data.
Capetillo has previously posted about weight management topics, but without seeing this specific video, we can't determine whether they're making accurate statements about dosing, side effects, or expected outcomes.
What do we actually know about GLP-1 medications?
The clinical evidence for GLP-1 receptor agonists is strong and specific. Semaglutide at 2.4mg (Wegovy) produced 14.9% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). Tirzepatide at 15mg led to 20.9% weight reduction in the SURMOUNT-1 study (Jastreboff et al., NEJM, 2022).
These medications work by mimicking the GLP-1 hormone, which slows gastric emptying and reduces appetite. Common side effects include nausea, vomiting, and diarrhea, particularly during dose escalation.
Starting doses are typically 0.25mg weekly for semaglutide, increasing gradually to the maintenance dose of 2.4mg. The drugs aren't magic pills and require lifestyle changes for optimal results.
What misinformation circulates about these drugs?
TikTok is filled with problematic claims about GLP-1 medications. Common myths include the idea that you can eat whatever you want while taking them, or that weight loss is permanent without continued use.
The STEP 1 extension study showed that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. This contradicts claims that these medications provide permanent weight loss.
Another frequent misconception involves "Ozempic face," a term that lacks clinical definition. While rapid weight loss can affect facial appearance, this isn't specific to GLP-1 medications. The phenomenon occurs with any significant weight reduction.
What should you know about GLP-1 social media content?
Always verify claims about these medications against published clinical trials. The FDA approval process for semaglutide and tirzepatide involved thousands of participants across multiple studies spanning several years.
Be skeptical of content creators who don't cite specific studies or provide vague claims about "amazing results." Real clinical data shows average weight loss percentages, not cherry-picked success stories.
For accurate information about GLP-1 medications, consult healthcare providers rather than social media influencers. These are prescription medications with specific indications, contraindications, and monitoring requirements that can't be adequately covered in short-form video content.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @paucapetillog's GLP-1 response video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@paucapetillog's GLP-1 response video, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications that activate incretin pathways to reduce appetite and slow gastric emptying.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications that activate incretin pathways to reduce appetite and slow gastric emptying. Clinical trials show 15-21% average weight loss with continued use, but effects diminish when treatment stops.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications that activate incretin pathways to reduce appetite and slow gastric emptying. Clinical trials show 15-21% average weight loss with continued use, but effects diminish when treatment stops.
- Semaglutide 2.4mg produced 14.9% average weight loss at 68 weeks in the STEP 1 trial
- Tirzepatide 15mg led to 20.9% weight reduction in the SURMOUNT-1 study
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Semaglutide 2.4mg produced 14.9% average weight loss at 68 weeks in the STEP 1 trial
- Tirzepatide 15mg led to 20.9% weight reduction in the SURMOUNT-1 study
- Participants who stopped semaglutide regained two-thirds of lost weight within a year
- GLP-1 medications require gradual dose escalation starting at 0.25mg weekly
- Common side effects include nausea, vomiting, and diarrhea during titration
- These medications work by mimicking GLP-1 hormone to reduce appetite and slow digestion
- Social media claims about GLP-1 drugs should be verified against published clinical data
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Pau Capetillo · TikTok creator
2.2M views on this video
Respuesta a @Kika25 mi acusación favorita ✨
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Pau Capetillo, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.